Edoardo Simonetta

Edoardo Simonetta

Auto-generated profile, based on publicly available information

Edoardo Simonetta

Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
FAFrancesco Amati
Francesco Amati
ESEdoardo Simonetta
Edoardo Simonetta
AGAndrea Gramegna
Andrea Gramegna
PTPaolo Tarsia
Paolo Tarsia
MCMartina Contarini
Martina Contarini
SAStefano Aliberti
Stefano Aliberti
Bronchiectasis is a heterogeneous chronic disease. Heterogeneity characterises bronchiectasis not only in the stable state but also during exacerbations, despite evidence on clinical and biological aspects of bronchiectasis, exacerbations still remain poorly understood.Although the scientific community recognises that bacterial infection is a cornerstone in the development of bronchiectasis, there is a lack of data regarding other trigger factors for exacerbations. In addition, a huge amount of data suggest a primary role of neutrophils in the stable state and exacerbation of bronchiectasis, but the inflammatory reaction involves many other additional pathways. Cole's vicious cycle hypothesis illustrates how airway dysfunction, airway inflammation, infection and structural damage are linked. The introduction of the concept of a “vicious vortex” stresses the complexity of the relationships between the components of the cycle. In this model of disease, exacerbations work as a catalyst, accelerating the progression of disease. The roles of microbiology and inflammation need to be considered as closely linked and will need to be investigated in different ways to collect samples. Clinical and translational research is of paramount importance to achieve a better comprehension of the pathophysiology of bronchiectasis, microbiology and inflammation both in the stable state and during exacerbations.

1 December 2018 in Respiratory Medicine
Verified
Journal Article
Closed access
DRDejan Radovanovic
Dejan Radovanovic
PSPierachille Santus
Pierachille Santus
Francesco BlasiFrancesco Blasi
Francesco Blasi
Giovanni SotgiuGiovanni Sotgiu
Giovanni Sotgiu
FDFrancesca D'ARcangelo
Francesca D'ARcangelo
SAStefano Aliberti
Stefano Aliberti

Verified
Journal Article
Open access
PDF file
Paola FaverioPaola Faverio
Paola Faverio
ASAnna Stainer
Anna Stainer
GBGiulia Bonaiti
Giulia Bonaiti
SZStefano C. Zucchetti
Stefano C. Zucchetti
ESEdoardo Simonetta
Edoardo Simonetta
SAStefano Aliberti
Stefano Aliberti
Chronic airway infection is a key aspect of the pathogenesis of bronchiectasis. A growing interest has been raised on non-tuberculous mycobacteria (NTM) infection. We aimed at describing the clinical characteristics, diagnostic process, therapeutic options and outcomes of bronchiectasis patients with pulmonary NTM (pNTM) disease. This was a prospective, observational study enrolling 261 adult bronchiectasis patients during the stable state at the San Gerardo Hospital, Monza, Italy, from 2012 to 2015. Three groups were identified: pNTM disease; chronic P. aeruginosa infection; chronic infection due to bacteria other than P. aeruginosa. NTM were isolated in 32 (12%) patients, and among them, a diagnosis of pNTM disease was reached in 23 cases. When compared to chronic P. aeruginosa infection, patients with pNTM were more likely to have cylindrical bronchiectasis and a “tree-in-bud” pattern, a history of weight loss, a lower disease severity and a lower number of pulmonary exacerbations. Among pNTM patients who started treatment, 68% showed a radiological improvement, and 37% achieved culture conversion without recurrence, while 21% showed NTM isolation recurrence. NTM isolation seems to be a frequent event in bronchiectasis patients, and few parameters might help to suspect NTM infection. Treatment indications and monitoring still remain an important area for future research.

2 July 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
MOMartina Oriano
Martina Oriano
AGAndrea Gramegna
Andrea Gramegna
FAFrancesco Amati
Francesco Amati
ADAlice D’adda
Alice D’adda
MGMichele Gaffuri
Michele Gaffuri
SAStefano Aliberti
Stefano Aliberti
Although bronchiectasis pathophysiology has been historically understood around the presence of airway neutrophilic inflammation, recent experiences are consistent with the identification of a type 2 inflammation (T2) high endotype in bronchiectasis. In order to evaluate prevalence and clinical characteristics of bronchiectasis patients with a T2-high endotype and explore their response to biologicals, two studies were carried out. In a cross-sectional study, bronchiectasis adults without asthma underwent clinical, radiological, and microbiological assessment, along with blood eosinophils and oral fractional exhaled nitric oxide (FeNO) evaluation, during stable state. Prevalence and characteristics of patients with a T2- high endotype (defined by the presence of either eosinophils blood count ≥300 cells·µL−1 or oral FeNO ≥ 25 dpp) were reported. A case series of severe asthmatic patients with concomitant bronchiectasis treated with either mepolizumab or benralizumab was evaluated, and patients’ clinical data pre- and post-treatment were analyzed up to 2 years of follow up. Among bronchiectasis patients without asthma enrolled in the cross-sectional study, a T2-high endotype was present in 31% of them. These patients exhibited a more severe disease, high dyspnea severity, low respiratory function, and high impact on quality of life. Among the five patients with severe eosinophilic asthma and concomitant bronchiectasis included in the series, treatment with either mepolizumab or benralizumab significantly reduced the exacerbation rate with an effect that persists for up to 2 years of follow up. If validated across different settings, our data suggest the need to design randomized controlled trials on biological treatments targeting the T2-high endotype in bronchiectasis patients.

Verified
Journal Article
Open access
PDF file
FAFrancesco Amati
Francesco Amati
ASAnna Stainer
Anna Stainer
MMMarco Mantero
Marco Mantero
AGAndrea Gramegna
Andrea Gramegna
ESEdoardo Simonetta
Edoardo Simonetta
SAStefano Aliberti
Stefano Aliberti
Interstitial lung diseases represent a heterogeneous and wide group of diseases in which factors leading to disease initiation and progression are not fully understood. Recent evidence suggests that the lung microbiome might influence the pathogenesis and progression of interstitial lung diseases. In recent years, the utilization of culture-independent methodologies has allowed the identification of complex and dynamic communities of microbes, in patients with interstitial lung diseases. However, the potential mechanisms by which these changes may drive disease pathogenesis and progression are largely unknown. The aim of this review is to discuss the role of the altered lung microbiome in several interstitial lung diseases. Untangling the host–microbiome interaction in the lung and airway of interstitial lung disease patients is a research priority. Thus, lung dysbiosis is a potentially treatable trait across several interstitial lung diseases, and its proper characterization and treatment might be crucial to change the natural history of these diseases and improve outcomes.

1 November 2020 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
ABA. Bandera
A. Bandera
SAS. Aliberti
S. Aliberti
RGR. Gualtierotti
R. Gualtierotti
MBM. Baldini
M. Baldini
Francesco BlasiFrancesco Blasi
Francesco Blasi
IMI. Monti
I. Monti